A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

NCT01789242 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis
Systemic Light Chain Amyloidosis

Interventions

DRUG: Carfilzomib
DRUG: Dexamethasone

Sponsor

Criterium, Inc.

Collaborators

[object Object]